Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode
Abstract Aims Renin–angiotensin–aldosterone system inhibitors (RAASi) are foundational in the management of heart failure (HF) and chronic kidney disease (CKD) but increase the risk of hyperkalaemia. To facilitate continuation of RAASi therapy, guidelines suggest managing hyperkalaemia using newer p...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Oxford University Press
2025-06-01
|
| Rangatū: | ESC Heart Failure |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1002/ehf2.15171 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|